PDB Short entry for 2XAB HEADER CHAPERONE 30-MAR-10 2XAB TITLE STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA,; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 9-236; COMPND 5 SYNONYM: HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN COMPND 6 NY-REN-38, HSP90; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS CANCER, CHAPERONE, ATP-BINDING, NUCLEOTIDE-BINDING, STRESS RESPONSE EXPDTA X-RAY DIFFRACTION AUTHOR C.W.MURRAY,M.G.CARR,O.CALLAGHAN,G.CHESSARI,M.CONGREVE,S.COWAN, AUTHOR 2 J.E.COYLE,R.DOWNHAM,E.FIGUEROA,M.FREDERICKSON,B.GRAHAM,R.MCMENAMIN, AUTHOR 3 M.A.O'BRIAN,S.PATEL,T.R.PHILLIPS,G.WILLIAMS,A.J.WOODHEAD, AUTHOR 4 A.J.A.WOOLFORD REVDAT 4 04-APR-18 2XAB 1 REMARK REVDAT 3 01-APR-15 2XAB 1 JRNL REVDAT 2 06-JUL-11 2XAB 1 JRNL REMARK REVDAT 1 11-AUG-10 2XAB 0 JRNL AUTH A.J.WOODHEAD,H.ANGOVE,M.G.CARR,G.CHESSARI,M.CONGREVE, JRNL AUTH 2 J.E.COYLE,J.COSME,B.GRAHAM,P.J.DAY,R.DOWNHAM,L.FAZAL, JRNL AUTH 3 R.FELTELL,E.FIGUEROA,M.FREDERICKSON,J.LEWIS,R.MCMENAMIN, JRNL AUTH 4 C.W.MURRAY,M.A.O'BRIEN,L.PARRA,S.PATEL,T.PHILLIPS,D.C.REES, JRNL AUTH 5 S.RICH,D.SMITH,G.TREWARTHA,M.VINKOVIC,B.WILLIAMS, JRNL AUTH 6 A.J.WOOLFORD JRNL TITL DISCOVERY OF JRNL TITL 2 (2,4-DIHYDROXY-5-ISOPROPYLPHENYL) JRNL TITL 3 -[5-(4-METHYLPIPERAZIN-1-YLMETHYL)-1, JRNL TITL 4 3-DIHYDROISOINDOL-2-YL]METHANONE (AT13387), A NOVEL JRNL TITL 5 INHIBITOR OF THE MOLECULAR CHAPERONE HSP90 BY FRAGMENT BASED JRNL TITL 6 DRUG DESIGN. JRNL REF J.MED.CHEM. V. 53 5956 2010 JRNL REFN ISSN 0022-2623 JRNL PMID 20662534 JRNL DOI 10.1021/JM100060B REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT 2.9.3 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SMART,VONRHEIN,WOMACK, REMARK 3 : MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 43.31 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.6 REMARK 3 NUMBER OF REFLECTIONS : 45150 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.206 REMARK 3 R VALUE (WORKING SET) : 0.204 REMARK 3 FREE R VALUE : 0.236 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.050 REMARK 3 FREE R VALUE TEST SET COUNT : 2282 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.95 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.56 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2868 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2301 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2737 REMARK 3 BIN R VALUE (WORKING SET) : 0.2280 REMARK 3 BIN FREE R VALUE : 0.2737 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.57 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 131 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3272 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 44 REMARK 3 SOLVENT ATOMS : 541 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 26.03 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.17 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 3.86520 REMARK 3 B22 (A**2) : -4.36000 REMARK 3 B33 (A**2) : 0.49470 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.216 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.155 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.139 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.141 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.132 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.948 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.930 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3418 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 4629 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1241 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 102 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 492 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3418 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 469 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4430 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 BOND ANGLES (DEGREES) : 1.01 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 6.01 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.26 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: IDEAL-DIST CONTACT TERM CONTACT SETUP. REMARK 3 ALL ATOMS HAVE CCP4 ATOM TYPE FROM LIBRARY. REMARK 4 REMARK 4 2XAB COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 30-MAR-10. REMARK 100 THE DEPOSITION ID IS D_1290043482. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : D*TREK REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 45815 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 46.250 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.6 REMARK 200 DATA REDUNDANCY : 3.310 REMARK 200 R MERGE (I) : 0.11000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.79 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.55 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 32.28300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 44.60400 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 32.28300 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 44.60400 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A2023 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -12 REMARK 465 GLY A -11 REMARK 465 SER A -10 REMARK 465 SER A -9 REMARK 465 HIS A -8 REMARK 465 HIS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 HIS A -4 REMARK 465 HIS A -3 REMARK 465 SER A -2 REMARK 465 SER A -1 REMARK 465 GLY A 0 REMARK 465 LEU A 1 REMARK 465 VAL A 2 REMARK 465 PRO A 3 REMARK 465 ARG A 4 REMARK 465 GLY A 5 REMARK 465 SER A 6 REMARK 465 HIS A 7 REMARK 465 MET A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 MET A 12 REMARK 465 GLU A 13 REMARK 465 GLU A 14 REMARK 465 GLU A 15 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 465 MET B -12 REMARK 465 GLY B -11 REMARK 465 SER B -10 REMARK 465 SER B -9 REMARK 465 HIS B -8 REMARK 465 HIS B -7 REMARK 465 HIS B -6 REMARK 465 HIS B -5 REMARK 465 HIS B -4 REMARK 465 HIS B -3 REMARK 465 SER B -2 REMARK 465 SER B -1 REMARK 465 GLY B 0 REMARK 465 LEU B 1 REMARK 465 VAL B 2 REMARK 465 PRO B 3 REMARK 465 ARG B 4 REMARK 465 GLY B 5 REMARK 465 SER B 6 REMARK 465 HIS B 7 REMARK 465 MET B 8 REMARK 465 ASP B 9 REMARK 465 GLN B 10 REMARK 465 PRO B 11 REMARK 465 MET B 12 REMARK 465 GLU B 13 REMARK 465 GLU B 14 REMARK 465 GLU B 15 REMARK 465 GLU B 225 REMARK 465 ARG B 226 REMARK 465 ASP B 227 REMARK 465 LYS B 228 REMARK 465 GLU B 229 REMARK 465 VAL B 230 REMARK 465 SER B 231 REMARK 465 ASP B 232 REMARK 465 ASP B 233 REMARK 465 GLU B 234 REMARK 465 ALA B 235 REMARK 465 GLU B 236 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 224 CA C O CB CG CD CE REMARK 470 LYS A 224 NZ REMARK 470 LYS B 224 CA C O CB CG CD CE REMARK 470 LYS B 224 NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 166 -140.77 60.89 REMARK 500 GLU A 178 72.51 30.50 REMARK 500 ARG A 182 137.15 -173.71 REMARK 500 TYR B 38 109.90 -165.96 REMARK 500 ALA B 111 -127.90 56.22 REMARK 500 ALA B 166 -142.35 61.79 REMARK 500 GLU B 178 75.49 -153.20 REMARK 500 ARG B 182 136.54 -174.83 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH B2138 DISTANCE = 6.13 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE VHD A 1224 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE VHD B 1224 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2CDD RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO- BENZOL(1,4)DIOXIN-6-YL)-5- REMARK 900 METHYL-1H- PYRAZOL-3-YL)-6-ETHYL-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY- 17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3- TRIMETHOXY-BENZYL)-9H-PURIN- REMARK 900 6YLAMINE REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN REMARK 900 COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY REMARK 900 NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE REMARK 900 ANALOGS REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE REMARK 900 HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9H-PURIN- REMARK 900 6-YLAMINE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)- REMARK 900 PIERAZIN-1-YL)-1H- PYRAZOL-3-YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN- 1-YL-1H-PYRAZOL-3-YL)- REMARK 900 BENZENE-1,2-DIOL REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9-PENT-9H- REMARK 900 PURIN-6- YLAMINE REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-4- YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2- CHLORO-3,4,5-TRIMETHOXY-BENZYL) REMARK 900 -9H-PURIN- 6-YLAMINE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4, 5-TRIMETHOXY-BENZYL)-9H- REMARK 900 PURIN-6-YLAMINE REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL REMARK 900 THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H71 REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3] DIOXOL-,5-YLMETHYL-9-BUTYL-2- REMARK 900 FLUORO-9H- PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-2-FLUORO- REMARK 900 9H-PURIN-6- YLAMINE REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4- DIHYDROXY-PHENYL)-4-PIPERAZIN-1- REMARK 900 YL-2H- PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE REMARK 900 INHIBITOR PU-H64 REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4, 5-TRIMETHOXY-BENZYL)-9-PENT- REMARK 900 4-YLNYL-9H- PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE- BASED INHIBITOR BINDING REMARK 900 TO HSP90 ISOFORMS REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5- DIMETHOXY-BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4- METHOXY-BENZYL)-9H-PURIN-6- REMARK 900 YLAMINE REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN- BINDING DOMAIN REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE- 4-CARBOXAMIDES AS REMARK 900 INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 REMARK 900 CHAPERONE DBREF 2XAB A 9 236 UNP P07900 HS90A_HUMAN 9 236 DBREF 2XAB B 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 2XAB MET A -12 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY A -11 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER A -10 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER A -9 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -8 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -7 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -6 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -5 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -4 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A -3 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER A -2 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER A -1 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY A 0 UNP P07900 EXPRESSION TAG SEQADV 2XAB LEU A 1 UNP P07900 EXPRESSION TAG SEQADV 2XAB VAL A 2 UNP P07900 EXPRESSION TAG SEQADV 2XAB PRO A 3 UNP P07900 EXPRESSION TAG SEQADV 2XAB ARG A 4 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY A 5 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER A 6 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS A 7 UNP P07900 EXPRESSION TAG SEQADV 2XAB MET A 8 UNP P07900 EXPRESSION TAG SEQADV 2XAB MET B -12 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY B -11 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER B -10 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER B -9 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -8 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -7 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -6 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -5 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -4 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B -3 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER B -2 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER B -1 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY B 0 UNP P07900 EXPRESSION TAG SEQADV 2XAB LEU B 1 UNP P07900 EXPRESSION TAG SEQADV 2XAB VAL B 2 UNP P07900 EXPRESSION TAG SEQADV 2XAB PRO B 3 UNP P07900 EXPRESSION TAG SEQADV 2XAB ARG B 4 UNP P07900 EXPRESSION TAG SEQADV 2XAB GLY B 5 UNP P07900 EXPRESSION TAG SEQADV 2XAB SER B 6 UNP P07900 EXPRESSION TAG SEQADV 2XAB HIS B 7 UNP P07900 EXPRESSION TAG SEQADV 2XAB MET B 8 UNP P07900 EXPRESSION TAG SEQRES 1 A 249 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 A 249 LEU VAL PRO ARG GLY SER HIS MET ASP GLN PRO MET GLU SEQRES 3 A 249 GLU GLU GLU VAL GLU THR PHE ALA PHE GLN ALA GLU ILE SEQRES 4 A 249 ALA GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER SEQRES 5 A 249 ASN LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SEQRES 6 A 249 SER ASP ALA LEU ASP LYS ILE ARG TYR GLU SER LEU THR SEQRES 7 A 249 ASP PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE SEQRES 8 A 249 ASN LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE SEQRES 9 A 249 VAL ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE SEQRES 10 A 249 ASN ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA SEQRES 11 A 249 PHE MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET SEQRES 12 A 249 ILE GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU SEQRES 13 A 249 VAL ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP SEQRES 14 A 249 ASP GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER SEQRES 15 A 249 PHE THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG SEQRES 16 A 249 GLY THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR SEQRES 17 A 249 GLU TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS SEQRES 18 A 249 LYS HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE SEQRES 19 A 249 VAL GLU LYS GLU ARG ASP LYS GLU VAL SER ASP ASP GLU SEQRES 20 A 249 ALA GLU SEQRES 1 B 249 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 B 249 LEU VAL PRO ARG GLY SER HIS MET ASP GLN PRO MET GLU SEQRES 3 B 249 GLU GLU GLU VAL GLU THR PHE ALA PHE GLN ALA GLU ILE SEQRES 4 B 249 ALA GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER SEQRES 5 B 249 ASN LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SEQRES 6 B 249 SER ASP ALA LEU ASP LYS ILE ARG TYR GLU SER LEU THR SEQRES 7 B 249 ASP PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE SEQRES 8 B 249 ASN LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE SEQRES 9 B 249 VAL ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE SEQRES 10 B 249 ASN ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA SEQRES 11 B 249 PHE MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET SEQRES 12 B 249 ILE GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU SEQRES 13 B 249 VAL ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP SEQRES 14 B 249 ASP GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER SEQRES 15 B 249 PHE THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG SEQRES 16 B 249 GLY THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR SEQRES 17 B 249 GLU TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS SEQRES 18 B 249 LYS HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE SEQRES 19 B 249 VAL GLU LYS GLU ARG ASP LYS GLU VAL SER ASP ASP GLU SEQRES 20 B 249 ALA GLU HET VHD A1224 22 HET VHD B1224 22 HETNAM VHD 4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)-6-(1- HETNAM 2 VHD METHYLETHYL)BENZENE-1,3-DIOL FORMUL 3 VHD 2(C18 H19 N O3) FORMUL 5 HOH *541(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 ASN A 40 GLU A 42 5 3 HELIX 3 3 ILE A 43 LEU A 64 1 22 HELIX 4 4 ASP A 66 ASP A 71 5 6 HELIX 5 5 THR A 99 ASN A 105 1 7 HELIX 6 6 ASN A 106 THR A 109 5 4 HELIX 7 7 ILE A 110 ALA A 124 1 15 HELIX 8 8 ASP A 127 GLY A 135 5 9 HELIX 9 9 VAL A 136 LEU A 143 5 8 HELIX 10 10 GLU A 192 LEU A 198 5 7 HELIX 11 11 GLU A 199 SER A 211 1 13 HELIX 12 12 GLN B 23 THR B 36 1 14 HELIX 13 13 GLU B 42 ASP B 66 1 25 HELIX 14 14 PRO B 67 ASP B 71 5 5 HELIX 15 15 THR B 99 THR B 109 1 11 HELIX 16 16 GLY B 114 ALA B 124 1 11 HELIX 17 17 ASP B 127 GLY B 135 5 9 HELIX 18 18 VAL B 136 LEU B 143 5 8 HELIX 19 19 GLN B 194 LEU B 198 5 5 HELIX 20 20 GLU B 199 SER B 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SHEET 1 BA 8 VAL B 17 ALA B 21 0 SHEET 2 BA 8 SER B 169 THR B 174 -1 O PHE B 170 N PHE B 20 SHEET 3 BA 8 TYR B 160 SER B 164 -1 O ALA B 161 N ARG B 173 SHEET 4 BA 8 ALA B 145 LYS B 153 -1 O VAL B 148 N SER B 164 SHEET 5 BA 8 GLY B 183 LEU B 190 -1 O GLY B 183 N LYS B 153 SHEET 6 BA 8 THR B 88 ASP B 93 -1 O LEU B 89 N LEU B 188 SHEET 7 BA 8 ILE B 78 ASN B 83 -1 O ASN B 79 N VAL B 92 SHEET 8 BA 8 ILE B 218 LEU B 220 1 O THR B 219 N LEU B 80 CISPEP 1 GLY A 177 GLU A 178 0 -0.49 SITE 1 AC1 13 ASN A 51 ASP A 54 ALA A 55 ASP A 93 SITE 2 AC1 13 ILE A 96 GLY A 97 MET A 98 LEU A 107 SITE 3 AC1 13 PHE A 138 THR A 184 VAL A 186 HOH A2118 SITE 4 AC1 13 HOH A2246 SITE 1 AC2 12 ASN B 51 ASP B 54 ALA B 55 ASP B 93 SITE 2 AC2 12 ILE B 96 GLY B 97 MET B 98 PHE B 138 SITE 3 AC2 12 THR B 184 VAL B 186 HOH B2146 HOH B2295 CRYST1 64.566 89.208 99.079 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015488 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011210 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010093 0.00000